Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH CongressGlobeNewsWire • 05/27/22
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH TrialGlobeNewsWire • 05/03/22
Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 03/23/22
Has Hepion Pharmaceuticals, Inc. (HEPA) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 03/02/22
Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company's Strategic Medical Affairs in AsiaGlobeNewsWire • 02/15/22
Hepion Pharmaceuticals' Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer StudyGlobeNewsWire • 01/26/22
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431GlobeNewsWire • 01/06/22
Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect ConferenceGlobeNewsWire • 01/05/22
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver CancerGlobeNewsWire • 12/21/21
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer StudyGlobeNewsWire • 11/16/21
Anti-Cancer Mechanism of Hepion Pharmaceuticals' CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021GlobeNewsWire • 11/10/21
All Endpoints Met in Hepion Pharmaceuticals' Drug-Drug Interaction Study with CRV431GlobeNewsWire • 09/29/21
Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate DrugSeeking Alpha • 09/21/21
Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION' Clinical Trial of CRV431 in NASHGlobeNewsWire • 09/10/21
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of StockholdersGlobeNewsWire • 07/23/21